Design Therapeutics
DSGN
79 hedge funds and large institutions have $667M invested in Design Therapeutics in 2022 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 18 reducing their positions, and 10 closing their positions.
603% more call options, than puts
Call options by funds: $7.91M | Put options by funds: $1.13M
83% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 18
50% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 10
23% more capital invested
Capital invested by funds: $542M → $667M (+$126M)
7% more funds holding
Funds holding: 74 → 79 (+5)
2.14% more ownership
Funds ownership: 69.36% → 71.5% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$18M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$11.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$9.15M |
| 4 |
Janus Henderson Group
London,
|
+$8.38M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$9.95M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.67M |
| 3 |
AG
Artal Group
Luxembourg
|
-$5.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.2M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.94M |
DSGN Hedge Fund Activity: Q3 2022 in Review
79 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2022, worth a combined $667M — up 23% from $542M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new DSGN positions and 10 closed out — a net gain of 5 holders — while 33 added to existing stakes and 18 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $18M. The largest seller was Cormorant Asset Management, cutting an estimated $9.95M.
- 79 institutional investors held Design Therapeutics (DSGN) as of Q3 2022, up from 74 in Q2 2022.
- Funds reported $667M of Design Therapeutics stock for Q3 2022, up 23% quarter-over-quarter.
- 15 funds opened new Design Therapeutics positions in Q3 2022 and 10 closed out, a net change of +5 holders.
- The largest Design Therapeutics buyer in Q3 2022 was Goldman Sachs, an estimated $18M added.
- The largest Design Therapeutics seller in Q3 2022 was Cormorant Asset Management, an estimated $9.95M sold.
Based on aggregated 13F filings for Q3 2022.